Objective: To assess the effect of oral cannabidiol (CBD) administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy.
Design: Randomized blinded controlled clinical trial.
Animals: 26 client-owned dogs with intractable idiopathic epilepsy.
Procedures: Dogs were randomly assigned to a CBD (n = 12) or placebo (14) group. The CBD group received CBD-infused oil (2.5 mg/kg [1.1 mg/lb], PO) twice daily for 12 weeks in addition to existing antiepileptic treatments, and the placebo group received noninfused oil under the same conditions. Seizure activity, adverse effects, and plasma CBD concentrations were compared between groups.
Results: 2 dogs in the CBD group developed ataxia and were withdrawn from the study. After other exclusions, 9 dogs in the CBD group and 7 in the placebo group were included in the analysis. Dogs in the CBD group had a significant (median change, 33%) reduction in seizure frequency, compared with the placebo group. However, the proportion of dogs considered responders to treatment (≥ 50% decrease in seizure activity) was similar between groups. Plasma CBD concentrations were correlated with reduction in seizure frequency. Dogs in the CBD group had a significant increase in serum alkaline phosphatase activity. No adverse behavioral effects were reported by owners.
Conclusions and clinical relevance: Although a significant reduction in seizure frequency was achieved for dogs in the CBD group, the proportion of responders was similar between groups. Given the correlation between plasma CBD concentration and seizure frequency, additional research is warranted to determine whether a higher dosage of CBD would be effective in reducing seizure activity by ≥ 50%.
Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671. Epilepsy Curr. 2019. PMID: 30955420 Free PMC article.
Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.Pediatrics. 2006 Aug;118(2):e371-8. doi: 10.1542/peds.2006-0148. Epub 2006 Jul 17. Pediatrics. 2006. PMID: 16847080 Clinical Trial.
Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.Drugs. 2018 Nov;78(17):1791-1804. doi: 10.1007/s40265-018-0992-5. Drugs. 2018. PMID: 30390221
Efficacy of cannabinoids in paediatric epilepsy.Dev Med Child Neurol. 2019 Jan;61(1):13-18. doi: 10.1111/dmcn.14087. Epub 2018 Nov 6. Dev Med Child Neurol. 2019. PMID: 30402932 Review.
Epilepsy and Cannabis: A Literature Review.Cureus. 2018 Sep 10;10(9):e3278. doi: 10.7759/cureus.3278. Cureus. 2018. PMID: 30443449 Free PMC article. Review.
Cited by 4 articles
Cannabinoid, Terpene, and Heavy Metal Analysis of 29 Over-the-Counter Commercial Veterinary Hemp Supplements.Vet Med (Auckl). 2020 Apr 15;11:45-55. doi: 10.2147/VMRR.S248712. eCollection 2020. Vet Med (Auckl). 2020. PMID: 32346530 Free PMC article.
Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs.Front Vet Sci. 2020 Feb 11;7:51. doi: 10.3389/fvets.2020.00051. eCollection 2020. Front Vet Sci. 2020. PMID: 32118071 Free PMC article.
Cannabis, One Health, and Veterinary Medicine: Cannabinoids' Role in Public Health, Food Safety, and Translational Medicine.Rambam Maimonides Med J. 2020 Jan 30;11(1):e0006. doi: 10.5041/RMMJ.10388. Rambam Maimonides Med J. 2020. PMID: 32017686 Free PMC article. Review.
Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats.Animals (Basel). 2019 Oct 19;9(10):832. doi: 10.3390/ani9100832. Animals (Basel). 2019. PMID: 31635105 Free PMC article.